Friday, July 09, 2021 11:44:24 PM
The argument that Nader stabilized the company may be true, but the complete narrative cited, references NP on NP, with no independent confirmation. It is spectacular to have a case attempted to be built in support of NP. Falls way short on independent verification of alleged facts( according the the known liar), so we have that. Unfortunately, all veracity of the case is lost when relying on the “ends justifies the means “ argument in an attempt to absolve him from the multitude of subsequent lies and failures. Moreover, the proffered case for NP cannot stand by any ethical barometer.
So, IF NP saved the company from BK and maybe he did, the argument is that self dealing, lies and other failures are OK? What about he hit his competency in raising money and just happens to be a failure in all matters related to Pharma execution. The case for that argument is more solid than “ he should be allowed to run amok” , because he put financing in place. Great be an advisor. Get performance shares for new money, but let an experienced pharma Executive take over leadership who can execute in the Pharma space. There is ambiguity with your case, but there is no ambiguity with all the on the record lies and failures. He may be able to raise money, but he sure cannot find the truth or run a pharma company.
The “ he saved CYDY from bankruptcy only to BK the company himself” is not a viable argument… nice attempt.
So, IF NP saved the company from BK and maybe he did, the argument is that self dealing, lies and other failures are OK? What about he hit his competency in raising money and just happens to be a failure in all matters related to Pharma execution. The case for that argument is more solid than “ he should be allowed to run amok” , because he put financing in place. Great be an advisor. Get performance shares for new money, but let an experienced pharma Executive take over leadership who can execute in the Pharma space. There is ambiguity with your case, but there is no ambiguity with all the on the record lies and failures. He may be able to raise money, but he sure cannot find the truth or run a pharma company.
The “ he saved CYDY from bankruptcy only to BK the company himself” is not a viable argument… nice attempt.
3X
God Bless America!
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
